Market Place
Sourcing Support
China SXT Pharmaceuticals Regains Nasdaq Compliance
17 Mar 2025 //
GLOBENEWSWIRE
China SXT Pharma Announces Share Consolidation
21 Feb 2025 //
GLOBENEWSWIRE
China SXT Pharmaceuticals Receives Nasdaq Bid Price Deficiency Notice
07 Oct 2024 //
GLOBENEWSWIRE
China SXT Pharma Regained Compliance with Nasdaq™s Minimum Bid Price Rule
26 Oct 2023 //
GLOBENEWSWIRE
China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split
04 Oct 2023 //
GLOBENEWSWIRE
China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split
18 May 2022 //
GLOBENEWSWIRE
SXT Pharma Enters into SPA to Issue 6% Convertible Promissory Note to $2.8M
14 Mar 2022 //
GLOBENEWSWIRE
China SXT Pharma Closes $4.1M Follow-on Underwritten Offering of Ordinary Shares
20 Jan 2022 //
GLOBENEWSWIRE
SXT Pharma Announces Proposed Underwritten Public Offering of Ordinary Shares
14 Jan 2022 //
GLOBENEWSWIRE
China SXT Pharmaceuticals Received Nasdaq Notification Letter
16 Dec 2021 //
PRNEWSWIRE
China SXT Obtains New Manufacturing Permit; Passes GMP Compliance-Inspection
18 Oct 2021 //
PRNEWSWIRE
China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split
19 Feb 2021 //
PRNASIA
China SXT granted 180-day extension to regain compliance with Nasdaq
08 Sep 2020 //
SEEKINGALPHA
China SXT PharmaAnnounces That It Received a Grant Supported by City Government
16 Mar 2020 //
PR NEWSWIRE
China SXT Pharmaceuticals, Inc. Announces Plans to Increase Production
24 Jan 2020 //
BUSINESS WIRE
China SXT Pharma announces pricing of a $15 Million PIPE financing
18 Apr 2019 //
BIOSPECTRUMASIA
China SXT Pharmaceuticals, Announces Pricing of a $15 Million PIPE Financing
17 Apr 2019 //
PR NEWSWIRE
China SXT Pharma Announces Financial Results for the Six Months
28 Mar 2019 //
PRASIA
China SXT Pharma Announces Final Closing of Initial Public Offering
18 Jan 2019 //
PR NEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.